FDA reviewing ingestible sensor device to monitor Abilify compliance

Found an issue? Give us feedback

The Brown University...arrow_drop_down

The Brown University Child & Adolescent Psychopharmacology Update

Article . 2015 . Peer-reviewed

License: Wiley Online Library User Agreement

Data sources: Crossref

FDA reviewing ingestible sensor device to monitor Abilify compliance

descriptionPublicationkeyboard_double_arrow_right Article 23 Nov 2015 English Publisher:WileyJournal:The Brown University Child & Adolescent Psychopharmacology Update, volume 17, pages 8-8 (issn: 1527-8395, eissn: 1556-7567,

Copyright policy )

doi: 10.1002/cpu.30091

FDA reviewing ingestible sensor device to monitor Abilify compliance

- Summary
- Metrics

Abstract

Although the Food and Drug Administration (FDA) is not allowed to discuss pending reviews, it has accepted the New Drug Application (NDA) for the combination product of Abilify, a brand of aripiprazole, embedded with a Proteus ingestible sensor. The FDA considered the NDA filed as of September 8. The below information comes from Otsuke Pharmaceuticals and Proteus.

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average